E Aytac1, Y Ozdemir1, G Ozuner2. 1. Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH, United States. 2. Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH, United States. Electronic address: ozunerg@ccf.org.
Abstract
INTRODUCTION AND AIM: Neuroendocrine carcinomas (NEC) of the large intestine are rare and aggressive neoplasms. This study was designed to review the experience at a single institution and analyze the outcomes to improve our understanding of these tumors. METHODS: The patients with NEC (high-grade neuroendocrine tumor) of the colon, rectum, and anal canal were identified from June 1993 to April 2011. Clinical features studied were patient demographics, presenting symptoms, tumor location, tumor stage, treatment status and length of follow-up. RESULTS: Twenty-five patients were identified. Stages of the diseases were I (n=5), II (n=1), III (n=10) and IV (n=9). Locations of the tumors were: colon (36%); rectum (28%) and anal canal (36%). Rectal bleeding (36%) and pain (32%) were the most common symptoms but 16% of patients were asymptomatic. Among the patients with local or locally advanced disease, only five patients had surgery alone. The remainder of the patients underwent chemotherapy with/without radiation. Mean follow-up was 33.7 ± 8.4 months after diagnosis. NEC of the large bowel and anal canal has very distinctive pathologic features and a very poor prognosis. More than one third of the patients with NEC had metastatic disease at the time of diagnosis. When these tumors are in an advanced stage none of the treatment modalities impact on survival. CONCLUSION: The present study showed the poor prognosis of these rare tumors.
INTRODUCTION AND AIM: Neuroendocrine carcinomas (NEC) of the large intestine are rare and aggressive neoplasms. This study was designed to review the experience at a single institution and analyze the outcomes to improve our understanding of these tumors. METHODS: The patients with NEC (high-grade neuroendocrine tumor) of the colon, rectum, and anal canal were identified from June 1993 to April 2011. Clinical features studied were patient demographics, presenting symptoms, tumor location, tumor stage, treatment status and length of follow-up. RESULTS: Twenty-five patients were identified. Stages of the diseases were I (n=5), II (n=1), III (n=10) and IV (n=9). Locations of the tumors were: colon (36%); rectum (28%) and anal canal (36%). Rectal bleeding (36%) and pain (32%) were the most common symptoms but 16% of patients were asymptomatic. Among the patients with local or locally advanced disease, only five patients had surgery alone. The remainder of the patients underwent chemotherapy with/without radiation. Mean follow-up was 33.7 ± 8.4 months after diagnosis. NEC of the large bowel and anal canal has very distinctive pathologic features and a very poor prognosis. More than one third of the patients with NEC had metastatic disease at the time of diagnosis. When these tumors are in an advanced stage none of the treatment modalities impact on survival. CONCLUSION: The present study showed the poor prognosis of these rare tumors.
Authors: Adam C Fields; Pamela Lu; Benjamin M Vierra; Frances Hu; Jennifer Irani; Ronald Bleday; Joel E Goldberg; Garrett M Nash; Nelya Melnitchouk Journal: Ann Surg Oncol Date: 2019-01-31 Impact factor: 5.344
Authors: Bruno Conte; Ben George; Michael Overman; Jeannelyn Estrella; Zhi-Qin Jiang; Amir Mehrvarz Sarshekeh; Renata Ferrarotto; Paulo M Hoff; Asif Rashid; James C Yao; Scott Kopetz; Arvind Dasari Journal: Clin Colorectal Cancer Date: 2015-12-29 Impact factor: 4.481
Authors: Emma Elizabeth Ilett; Seppo W Langer; Ingrid Holst Olsen; Birgitte Federspiel; Andreas Kjær; Ulrich Knigge Journal: Diagnostics (Basel) Date: 2015-04-08
Authors: Paweł Gut; Joanna Waligórska-Stachura; Agata Czarnywojtek; Nadia Sawicka-Gutaj; Maciej Bączyk; Katarzyna Ziemnicka; Kosma Woliński; Ariadna Zybek; Jakub Fischbach; Marek Ruchała Journal: Arch Med Sci Date: 2017-01-06 Impact factor: 3.318